Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB/RIF is Superior to Phenotypic Drug Susceptibility Testing

被引:11
作者
Xia, Hui [1 ]
Song, Yuanyuan [1 ]
Zheng, Yang [1 ]
Wang, Shengfen [1 ]
Zhao, Bing [1 ]
He, Wencong [1 ]
Liu, Dongxin [2 ]
Ou, Xichao [1 ]
Zhou, Yang [1 ]
Zhao, Yanlin [1 ]
机构
[1] Chinese Ctr Dis Control & Prevent, Natl Ctr TB Control & Prevent, 155 Changbai Rd, Beijing, Peoples R China
[2] Shenzhen Third Peoples Hosp, Natl Clin Res Ctr Infect Dis, Inst Hepatol, Shenzhen, Peoples R China
来源
INFECTION AND DRUG RESISTANCE | 2022年 / 15卷
关键词
Mycobacterium tuberculosis; rifampicin; borderline resistance; phenotypic drug susceptibility test; TOOL;
D O I
10.2147/IDR.S358301
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To compare the ability of detection of borderline rifampicin resistance in Mycobacterium tuberculosis between molecular assay and phenotypic drug susceptibility tests. Methods: Fifty-seven isolates with His445Leu, Asp435Tyr, Leu452Pro, Leu430Pro, His445Asn, Ile491Phe, and His445Ser mutations in rpoB gene identified by whole-genome sequencing conferring borderline rifampicin resistance were included. Molecular-based Xpert MTB/RIF, phenotypic Lowenstein-Jensen (L-J) medium-based drug susceptibility test (DST) with a critical concentration of 40.0 mu g/mL and minimal inhibitory concentration (MIC) assay were performed to detect borderline rifampicin resistance. Results: When using Xpert MTB/RIF, 48/57 (84.2%) isolates exhibited resistance to rifampicin. 25/57 (43.9%) and 33/57 (57.9%) isolates showed rifampicin resistance by L-J medium-based DST with 4 and 6 weeks of incubation, respectively. 30/57 (52.6%) and 40/57 (70.2%) strains were resistant to rifampicin by MIC method at cutoff values of 1.0 and 0.5 mu g/mL, respectively. The detection rate of rifampicin resistance of Xpert MTB/RIF was significantly higher than that of phenotypic methods (p < 0.001). Of the 57 isolates with borderline rpoB mutations, 5 (8.8%) had MICs of 0.25 or 0.12 mu g/mL, 22 (38.6%) had MICs of 0.5 mu g/mL or 1.0 mu g/mL, and 30 (52.6%) other isolates showed MICs >= 2.0 mu g/mL. Conclusion: Molecular-based Xpert MTB/RIF showed superior ability to detect borderline rifampicin resistance over phenotypic DST methods. Extending the incubation time of L-J DST or lowering the cutoff value of the MIC method can improve borderline rifampicin resistance detection.
引用
收藏
页码:1345 / 1352
页数:8
相关论文
共 25 条
  • [1] Occurrence of rpoB Mutations in Isoniazid-Resistant but Rifampin-Susceptible Mycobacterium tuberculosis Isolates from Germany
    Andres, Soenke
    Hillemann, Doris
    Ruesch-Gerdes, Sabine
    Richter, Elvira
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 590 - 592
  • [2] Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex
    Berrada, Zenda L.
    Lin, Shou-Yean Grace
    Rodwell, Timothy C.
    Duylinh Nguyen
    Schecter, Gisela F.
    Pham, Lucy
    Janda, J. Michael
    Elmaraachli, Wael
    Catanzaro, Antonino
    Desmond, Edward
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2016, 85 (02) : 177 - 181
  • [3] Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay
    Blakemore, Robert
    Story, Elizabeth
    Helb, Danica
    Kop, JoAnn
    Banada, Padmapriya
    Owens, Michelle R.
    Chakravorty, Soumitesh
    Jones, Martin
    Alland, David
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (07) : 2495 - 2501
  • [4] CLSI, 2018, CLSI supplement M62, V1st ed.
  • [5] Hu PL, 2019, J CLIN MICROBIOL, V57, DOI [10.1128/jcm.01707-18, 10.1128/JCM.01707-18]
  • [6] Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing
    Huo, Fengmin
    Ma, Yifeng
    Liu, Rongmei
    Ma, Liping
    Li, Shanshan
    Jiang, Guanglu
    Wang, Fen
    Shang, Yuanyuan
    Dong, Lingling
    Pang, Yu
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (08):
  • [7] Jo KW, 2017, TUBERC RESPIR DIS, V80, P270, DOI 10.4046/trd.2017.80.3.270
  • [8] Lee K, 2009, GLOB INST, P1
  • [9] Disputed rpoB Mutations in Mycobacterium tuberculosis and Tuberculosis Treatment Outcomes
    Lin, Wan-Hsuan
    Lee, Wei-Ting
    Tsai, Hsing-Yuan
    Jou, Ruwen
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (07)
  • [10] Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China
    Liu, Dongxin
    Huang, Fei
    Zhang, Guoliang
    He, Wencong
    Ou, Xichao
    He, Ping
    Zhao, Bing
    Zhu, Baoli
    Liu, Fei
    Li, Zhiyuan
    Liu, Chunfa
    Xia, Hui
    Wang, Shengfen
    Zhou, Yang
    Walker, Timothy M.
    Liu, Lei
    Crook, Derrick W.
    Zhao, Yanlin
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (05) : 731.e9 - 731.e15